Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease : experience from the Phase 3 ATTRACT study
dc.contributor.author | Hughes, Derralynn A. | pt_BR |
dc.contributor.author | Nicholls, Kathleen M. | pt_BR |
dc.contributor.author | Sunder-Plassmann, G. | pt_BR |
dc.contributor.author | Jovanovic, Ana | pt_BR |
dc.contributor.author | Feldt-Rasmussen, Ulla | pt_BR |
dc.contributor.author | Schiffmann, Raphael | pt_BR |
dc.contributor.author | Giugliani, Roberto | pt_BR |
dc.contributor.author | Jain, Vipul | pt_BR |
dc.contributor.author | Viereck, Christopher | pt_BR |
dc.contributor.author | Castelli, Jeffrey P. | pt_BR |
dc.contributor.author | Skuban, Nina | pt_BR |
dc.contributor.author | Barth, Jay | pt_BR |
dc.contributor.author | Bichet, Daniel G. | pt_BR |
dc.date.accessioned | 2019-10-25T03:46:43Z | pt_BR |
dc.date.issued | 2019 | pt_BR |
dc.identifier.issn | 1552-4833 | pt_BR |
dc.identifier.uri | http://hdl.handle.net/10183/200996 | pt_BR |
dc.format.mimetype | application/pdf | pt_BR |
dc.language.iso | eng | pt_BR |
dc.relation.ispartof | American journal of medical genetics. Part A. Hoboken, N.J. : Wiley-Blackwell. Vol. 179A (2019), p. 1069–1073 | pt_BR |
dc.rights | Open Access | en |
dc.subject | Terapia de reposição de enzimas | pt_BR |
dc.subject | Tratamento farmacológico | pt_BR |
dc.subject | Substituição de medicamentos | pt_BR |
dc.subject | Doença de Fabry | pt_BR |
dc.subject | Estudo clínico | pt_BR |
dc.title | Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease : experience from the Phase 3 ATTRACT study | pt_BR |
dc.type | Artigo de periódico | pt_BR |
dc.identifier.nrb | 001104115 | pt_BR |
dc.type.origin | Estrangeiro | pt_BR |
Files in this item
This item is licensed under a Creative Commons License
![](/themes/Mirage2Novo//images/lume/cc.png)
-
Journal Articles (39401)Health Sciences (10592)
-
Journal Articles (39401)Biological Sciences (3071)